The use of piroxicam as an adjuntive treatment for squamous cell carcinoma in the third eyelid of a horse.

Simone Iwabe; León Ramírez-López; Mónica Juárez-Sánchez

2009, Number 4

<< Back Next >>

Vet Mex 2009; 40 (4)

The use of piroxicam as an adjuntive treatment for squamous cell carcinoma in the third eyelid of a horse.

Iwabe S, Ramírez-López L, Juárez-Sánchez M

Full text

How to cite this article

Language: English/Spanish
References: 23
Page: 389-395
PDF size: 310.78 Kb.

ABSTRACT

The aim of this study was to evaluate the use of piroxicam as an adjuntive treatment for squamous cell carcinoma in a horse.In September 2007, a 10-year-old Thoroughbred gelding weighing 555 kg was seen by private ophthalmologist for showing abundant mucoid secretion, conjunctival hyperemia and granulation tissue on the third eyelid of the left eye. The patient was initially treated with antibiotics and anti-inflammatory drugs. A biopsy of the granulation tissue on the third eyelid was taken. The laboratory reported a non tumoral epithelial hiperplasia. After ten days of treatment, the size of the tumor slightly decreased, but after two weeks the horse showed no further improvement, so surgical treatment was elected. The third eyelid of the left eye was excised completely and the tumor was submitted for histopathological examination. The laboratory reported a squamous cell carcinoma. Postsurgical treatment included topical antibiotics and anti-inflammatory drugs, and piroxicam (80 mg PO SID). Ten months after surgery was performed, the horse showed no complications or signs of recurrence. Squamous cell carcinoma has been reported as the second most common tumor in horses. Non-steroidal anti-inflammatory drugs are potent inhibitors of the cyclooxygenases (COX). It has been demonstrated that COX-2 is overexpressed in several epithelial tumors; therefore, inhibitors of COX-2 can induce apoptosis of tumor cells and inhibit angiogenesis.

REFERENCES

1.GILGER BC, STOPPINI R. Diseases of the eyelids, conjunctiva, and nasolacrimal system. In: GILGER BC, editor. Equine ophthalmology. Missouri, Elsevier Saunders, 2005: 107-156.
2.BROOKS DE.Equine ophthalmology. In: GELLAT KN, editor. Textbook of veterinary ophthalmology. 3rd ed. Philadelphia, Williams and Williams, 1999: 1053-1116.
3.GELATT KN, MYERS VS, PERMAN V. Conjunctival squamous cell carcinoma in the horse. J Am Vet Med Assoc 1997; 165: 617-620.
4.DIBERNARDI L, DORE M, DAVIS AJ, OWENS JG, MOHAMMED SI, GUPTILL CF et al. Study of feline oral squamous cell carcinoma: potential target for cyclooxygenase inhibitor treatment. Prostaglandins Leukot Essent Fatty Acids 2007; 76: 245-250.
5.KAPS S, RICHTER M, PHILIPP M, BART M, EULE C, SPIESS BM. Primary invasive ocular squamous cell carcinoma in a horse. Vet Ophthalmol 2005; 8: 193-197.
6.RASSNICK KM, NJAA BL. Cyclooxygenase-2 immunoreactivity in equine ocular squamous cell carcinoma. J Vet Diagn Invest 2007; 19: 436-439.
7.SIRONI G, RICCABONI P, MERTEL L, CAMMARATA G, BROOKS DE. P53 protein expression in conjunctival squamous cell carcinomas of domestic animals. Vet Ophthalmol 1999; 2: 227-231.
8.ELLIS DR. Treatment of squamous cell carcinoma in a horse. Vet Rec 2006; 159: 462-463.
9.MOSUNIC CB, MOORE PA, CARMICHEAL KP, CHANDLER MJ, VIDYASHANKAR A, ZHAO Y et al. Effects of treatment with and without adjuvant radiation therapy on recurrence of ocular and adnexal squamous cell carcinoma in horses: 157 cases (1985-2002). J Am Vet Med Assoc 2004; 225: 1733-1738.
10.HILBERT BJ, FARREL RK, GRANT BD. Cryotherapy of periocular squamous cell carcinoma in the horse. J Am Vet Med Assoc 1977; 170: 1305-1308.
11.RAYNER SG, VAN ZYL N. The use of mitomycin C as an adjuntive treatment for equine ocular squamous cell carcinoma. Aust Vet J 2006; 84: 43-46.
12.THEON AP, PASCOE JR, GALUPPO LD, FISHER PE,GRIFFEY SM, MADIGAN JE. Comparison of perioperativeversus postoperative intratumoral administration of cisplatin fot treatment of cutaneous sarcoids and squamous cell carcinoma in horses. J Am Vet Med Assoc 1999; 215: 1655-1660.
13.DUGAN SJ, ROBERTS SM, CURTIS CR, SEVERIN GA. Prognostic factors and survival of horses with ocular/ adnexal squamous cell carcinoma: 147 cases (1978- 1988). J Am Vet Med Assoc 1991; 198: 298-303.
14.MCCOWAN C, STANLEY RG. Pigmented squamous cell carcinoma of the conjuntiva of a horse. Vet Ophthalmol 2004; 7: 421-423.
15.GEARHART PM, STEFICEK BA, PETERSEN-JONES SM. Hemangiosarcoma and squamous cell carcinoma in the third eyelid of a horse. Vet Ophthalmol 2007; 10: 121-126.
16.MOORE AS, BEAM SL, RASSNICK KM, PROVOST P. Long-term control of mucocutaneous squamous cell carcinoma and metastases in a horse using piroxicam. Equine Vet J 2003; 35: 715-718.
17.BRIDEAU C, VAN STADEN C, CHAN GA. In vitro effects of cyclooxygenase inhibitors in whole blood of horses, dogs, and cats. Am J Vet Res 2001; 62: 1755-1760.
18.ELCE YA, ORSINI JA, BLIKSLAGER AT. Expression of cyclooxygenase-1 and -2 in naturally occurring squamous cell carcinomas in horses. Am J Vet Res 2007; 68: 76-80.
19.MCINNIS CL, GIULIANO EA, JOHNSON PJ, TURK JR. Immunohistochemical evaluation of cyclooxygenase expression in corneal squamous cell carcinoma in horses. Am J Vet Res 2007; 68: 165-170.
20.SCHMIDT BR, GLICKMAN NW, DENICOLA DB, DE GORTARI AE, KNAPP DW. Evaluation of piroxicam for the treatment of oral squamous cell carcinoma in dogs. J Am Vet Med Assoc 2001; 218: 1783-1786.
21.KNOTTENBELT C, CHAMBERS G, GAULT E, ARGYLE DJ. The in vitro effects of piroxicam and meloxicam on canine cell lines. J Small An Pract 2006;47: 14-20.
22.KNAPP DW, RICHARDSON RC, CHAN TCK, BOTTOMS GD, WIDMER WR, DENICOLA DB et al. Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. J Vet Int Med 1994; 8: 273-278.